Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

Description: Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

Summary

‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Head And Neck Cancer Squamous Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Head And Neck Cancer Squamous Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Head And Neck Cancer Squamous Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Altor BioScience Corporation
Amgen Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CEL-SCI Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eisai Co., Ltd.
Eli Lilly and Company
Etubics Corporation
F. Hoffmann-La Roche Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genexine, Inc.
Genmab A/S
Glycotope GmbH
Hanmi Pharmaceuticals, Co. Ltd.
Horizon Pharma Plc
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Incyte Corporation
Innate Pharma S.A.
Inovio Pharmaceuticals, Inc.
IRX Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Mabion SA
MacroGenics, Inc.
Marsala Biotech Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Partners AG
Molplex Ltd.
Novartis AG
Oncobiologics, Inc.
Oncoylitics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Incorporated
Ono Pharmaceutical Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech Holding ASA
Pfizer Inc.
Sanofi
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Shionogi & Co., Ltd.
Sillajen Biotherapeutics
Symphogen A/S
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Threshold Pharmaceuticals, Inc.
Ubivac, LLC
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Bio Inc.
Vyriad

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
ABBV-221 - Drug Profile
AdIL-24 - Drug Profile
afatinib dimaleate - Drug Profile
alisertib - Drug Profile
AlloVax - Drug Profile
alpelisib - Drug Profile
ALT-803 - Drug Profile
AMG-319 - Drug Profile

Antibodies to Inhibit FRMD4A for Oncology - Drug Profile

Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

AV-203 - Drug Profile
avelumab - Drug Profile
axalimogene filolisbac - Drug Profile
AZD-5069 - Drug Profile
AZD-6738 - Drug Profile
AZD-9150 - Drug Profile
bleomycin sulfate - Drug Profile
BMS-986016 - Drug Profile
BNV-003 - Drug Profile
buparlisib hydrochloride - Drug Profile
cabazitaxel - Drug Profile
capmatinib - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
cetuximab - Drug Profile
cetuximab biobetter - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
copanlisib hydrochloride - Drug Profile
COTI-2 - Drug Profile
dalantercept - Drug Profile
Debio-1143 - Drug Profile
depatuxizumab - Drug Profile
DNA IL-12 - Drug Profile
DPV-001 - Drug Profile
DTP-348 - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
E-10A - Drug Profile
E-7046 - Drug Profile
EBC-46 - Drug Profile
EDC-2 - Drug Profile
elgemtumab - Drug Profile
enoblituzumab - Drug Profile
epacadostat - Drug Profile
ETBX-041 - Drug Profile
everolimus - Drug Profile
ficlatuzumab - Drug Profile
futuximab - Drug Profile
ganetespid - Drug Profile
gedatolisib - Drug Profile
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
GL-0817 - Drug Profile
golvatinib tartrate - Drug Profile
GS-10 - Drug Profile
GSK-2636771 - Drug Profile
GSK-2849330 - Drug Profile
GSK-3174998 - Drug Profile
GX-051 - Drug Profile
HF-10 - Drug Profile
HSV-1716 - Drug Profile
IC-1001 - Drug Profile
INCB-50465 - Drug Profile
INO-3106 - Drug Profile
INO-3112 - Drug Profile
interferon gamma-1b - Drug Profile
IRX-2 - Drug Profile
JX-929 - Drug Profile
KGP-94 - Drug Profile
KM-3174 - Drug Profile
KTN-3379 - Drug Profile
lenvatinib mesylate - Drug Profile
Leukocyte Interleukin - Drug Profile
LGK-974 - Drug Profile
lirilumab - Drug Profile
LN-145 - Drug Profile
LOXO-101 - Drug Profile
lumretuzumab - Drug Profile
masitinib - Drug Profile
MEDI-0562 - Drug Profile
merestinib - Drug Profile
MGCD-265 - Drug Profile
MGD-009 - Drug Profile
monalizumab - Drug Profile
Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
motolimod - Drug Profile
MP-0250 - Drug Profile
nilotinib - Drug Profile
nimotuzumab - Drug Profile
nivolumab - Drug Profile
NP-001 - Drug Profile
olaparib - Drug Profile
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Oncolytic Virus to Target CD46 for Recurrent Squamous Cell Carcinoma Head and Neck Cancer - Drug Profile
palbociclib - Drug Profile
panitumumab - Drug Profile
patritumab - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
PF-04518600 - Drug Profile
PF-06801591 - Drug Profile
pozotinib - Drug Profile
prexasertib - Drug Profile
Recombinant Peptide to Target EGFR for Oncology - Drug Profile
Recombinant Protein for Oncology - Drug Profile
rigosertib sodium - Drug Profile
S-488210 - Drug Profile
sacituzumab - Drug Profile
SB-01 - Drug Profile
seribantumab - Drug Profile
SF-1126 - Drug Profile
Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile
Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile
solarise - Drug Profile
Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
tarloxotinib bromide - Drug Profile
tisotumab vedotin - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
UBS-109 - Drug Profile
urelumab - Drug Profile
utomilumab - Drug Profile
varililumab - Drug Profile
Vas-01 - Drug Profile
VB-4847 - Drug Profile
vinflunine ditartrate - Drug Profile
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Investigation by Universities/Institutes, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AltobioScience Corporation, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Debiopharm International SA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotech Limited, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2016
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H1 2016
List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3746947/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3746947/
Office Code: SCH3X228

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr [ ]</th>
<th>Mrs [ ]</th>
<th>Dr [ ]</th>
<th>Miss [ ]</th>
<th>Ms [ ]</th>
<th>Prof [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email Address: *</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Job Title:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Organisation:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postal / Zip Code:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phone Number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fax Number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World